Xilio Therapeutics
41 hedge funds and large institutions have $133M invested in Xilio Therapeutics in 2022 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 8 increasing their positions, 13 reducing their positions, and 4 closing their positions.
New
Increased
Maintained
Reduced
Closed
less funds holding
Funds holding: →
less ownership
Funds ownership: →
less funds holding in top 10
Funds holding in top 10: →
less first-time investments, than exits
New positions opened: | Existing positions closed:
38% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 13
56% less capital invested
Capital invested by funds: $303M → $133M (-$170M)
Holders
41
Holding in Top 10
3
Calls
–
Puts
–
Top Buyers
| 1 | +$245K | |
| 2 | +$145K | |
| 3 | +$53.2K | |
| 4 |
Bank of New York Mellon
New York
|
+$48.1K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$23.3K |
Top Sellers
| 1 | -$592K | |
| 2 | -$533K | |
| 3 | -$480K | |
| 4 |
DKCM
Davidson Kempner Capital Management
New York
|
-$458K |
| 5 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
-$362K |